{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:52:33Z","timestamp":1786373553880,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>Nephrology has conducted few high\u2013quality clinical trials, and the trials that have been conducted have not resulted in the approval of new treatments for primary or inflammatory glomerular diseases. There are overarching process issues that affect the conduct of all clinical trials, but there are also some specialty\u2013specific issues. Within nephrology, primary glomerular diseases are rare, making adequate recruitment for meaningful trials difficult. Nephrologists need better ways, beyond histopathology, to phenotype patients with glomerular diseases and stratify the risk for progression to ESRD. Rigorous trial design is needed for the testing of new therapies, where most patients with glomerular diseases are offered the opportunity to enroll in a clinical trial if standard therapies have failed or are lacking. Training programs to develop a core group of kidney specialists with expertise in the design and implementation of clinical trials are also needed. Registries of patients with glomerular disease and observational studies can aid in the ability to determine realistic estimates of disease prevalence and inform trial design through a better understanding of the natural history of disease. Some proposed changes to the Common Rule, the federal regulations governing the ethical conduct of research involving humans, and the emerging use of electronic health records may facilitate the efficiency of initiating multicenter clinical trials. Collaborations among academia, government scientific and regulatory agencies, industry, foundations, and patient advocacy groups can accelerate therapeutic development for these complex diseases.<\/jats:p>","DOI":"10.2215\/cjn.00540116","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T23:04:04Z","timestamp":1474931044000},"page":"2234-2243","source":"Crossref","is-referenced-by-count":13,"title":["Glomerular Diseases: Registries and Clinical Trials"],"prefix":"10.2215","volume":"11","author":[{"given":"Marva M.","family":"Moxey-Mims","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Flessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Holzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Kaskel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Sedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/01.ASN.0000113164.35698.49","article-title":"Clinical trial in nephrology at hard end point?","volume":"15","author":"de Zeeuw","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.10.043","article-title":"The landscape of clinical trials in nephrology: A systematic review of","volume":"63","author":"Inrig","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ackd.2012.01.009","article-title":"Randomized controlled trials in nephrology: State of the evidence and critiquing the evidence","volume":"19","author":"Samuels","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1001\/jama.297.23.2630","article-title":"Chronic kidney disease and the public health: Gaps in evidence from interventional trials","volume":"297","author":"Himmelfarb","year":"2007","journal-title":"JAMA"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cts.12003","article-title":"Patient recruitment into a multicenter randomized clinical trial for kidney disease: Report of the focal segmental glomerulosclerosis clinical trial (FSGS CT)","volume":"6","author":"Ferris","year":"2013","journal-title":"Clin Transl Sci"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"54","author":"Levey","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfv106","article-title":"Moderator\u2019s view: Biomarkers in glomerular diseases--translated into patient care or lost in translation?","volume":"30","author":"Ronco","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1681\/ASN.2015010091","article-title":"Complete and partial remission as surrogate end points in membranous nephropathy","volume":"26","author":"Thompson","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"e0119947","DOI":"10.1371\/journal.pone.0119947","article-title":"Serum thiols as a biomarker of disease activity in lupus nephritis","volume":"10","author":"Lalwani","year":"2015","journal-title":"PLoS One"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ki.2010.485","article-title":"Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life","volume":"79","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2215\/CJN.11951214","article-title":"Human heredity and health (H3) in Africa Kidney Disease Research Network: A focus on methods in sub-Saharan Africa","volume":"10","author":"Osafo","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1740774512461859","article-title":"Overview, hurdles, and future work in adaptive designs: Perspectives from a National Institutes of Health-funded workshop","volume":"9","author":"Coffey","year":"2012","journal-title":"Clin Trials"},{"key":"B23-20230813","first-page":"238","article-title":"Specific requirements on content and format of labeling for human prescription drugs: Revision of \u201cpediatric use\u201d subsection in the labeling: Final rule","volume":"59","year":"1994","journal-title":"Fed Regist"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1542\/peds.2010-3487","article-title":"Extrapolation of adult data and other data in pediatric drug-development programs","volume":"128","author":"Dunne","year":"2011","journal-title":"Pediatrics"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/joim.12119","article-title":"Electronic health records: New opportunities for clinical research","volume":"274","author":"Coorevits","year":"2013","journal-title":"J Intern Med"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4300\/JGME-D-11-00147.1","article-title":"Getting off the \u201cgold standard\u201d: Randomized controlled trials and education research","volume":"3","author":"Sullivan","year":"2011","journal-title":"J Grad Med Educ"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMp1103502","article-title":"Pragmatic trials--guides to better patient care?","volume":"364","author":"Ware","year":"2011","journal-title":"N Engl J Med"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMp1512205","article-title":"Bringing the common rule into the 21st century","volume":"373","author":"Hudson","year":"2015","journal-title":"N Engl J Med"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/cts.12074","article-title":"Ohio CTSAs implement a reliant IRB model for investigator-initiated multicenter clinical trials","volume":"6","author":"Cola","year":"2013","journal-title":"Clin Transl Sci"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMsb1300760","article-title":"Randomized clinical trials--removing unnecessary obstacles","volume":"369","author":"Reith","year":"2013","journal-title":"N Engl J Med"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/ndt\/gfs447","article-title":"Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis","volume":"28","author":"Morris","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2215\/CJN.01600214","article-title":"Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis","volume":"9","author":"Hogan","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1056\/NEJMe1212368","article-title":"Trials in kidney disease--time to EVOLVE","volume":"367","author":"Perkovic","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201612000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:46:51Z","timestamp":1786369611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201612000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.00540116","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]}}}